Test Price
2,800 AEDโ Home Collection Available
CHRNA4 Gene Epilepsy, Nocturnal Frontal Lobe Type 1 Genetic Test in UAE
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% diagnostic sensitivity via ISO 9001:2015 accredited processing (Cert: INT/EGQ/2509DA/3139).
- Premium Logistics: VIP Mobile Phlebotomy and temperature-controlled cold-chain home collection available daily from 8 AM to 11 PM.
- Clinical Guidance: Telephonic post-test counselling by a DHA-licensed Consultant Medical Geneticist for result interpretation and family planning.
- Insurance: Direct billing verification via WhatsApp +971 54 548 8731.
- DHA Licensed Facility: DNA Labs UAE โ Licence No. 1143, Dubai Healthcare City.
Test Overview & Methodology
The CHRNA4 Genetic Test identifies pathogenic variants in the CHRNA4 gene linked to autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE). This next-generation sequencing analysis, coupled with confirmatory Sanger sequencing, enables precise molecular diagnosis, family cascade screening, and personalised treatment planning. The test is performed under ISO 9001:2015 certified processes and adheres to DHA and international neurogenetic standards.
| Feature | Our Test (CHRNA4 NGS) | Closest Alternative |
|---|---|---|
| Precision | Complete CHRNA4 gene sequencing plus deletion and duplication analysis | Single-site mutation genotyping or limited panel |
| Method | NGS with Sanger confirmation covering coding, intronic, and regulatory regions | Sanger only; deep intronic and regulatory variants missed |
| Turnaround | 3โ4 weeks (DHA-licensed local lab) | 4โ6 weeks (overseas referral) |
Physician Insight & Safety Protocols
โIdentifying a pathogenic CHRNA4 variant refines our diagnostic precision and guides family counselling. However, a molecular finding must always be interpreted alongside seizure semiology, EEG patterns, and three-generation pedigree analysis. This test empowers informed clinical decisions but does not replace a comprehensive neurological consultation.โ โ Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403.
Medication & Clinical Advisory
โ ๏ธ Important: Do not discontinue, adjust, or alter any prescribed antiepileptic medication without direct consultation with your treating neurologist. Genetic results complement clinical management and should never replace established therapeutic regimens.
Patient Exclusion Criteria & Emergency Red Flags
- Pregnancy requires specialist pre-test genetic counselling before proceeding.
- Inability to provide informed consent โ minors must comply with Federal Decree-Law No. 4 of 2016 on Medical Liability via a legal guardian.
- Active severe infection or uncontrolled seizure episode at time of sample collection.
- Emergency Red Flags: Prolonged seizure lasting longer than 5 minutes, status epilepticus, respiratory distress, or any immediate threat to life โ call 998 (UAE Emergency) without delay.
Patient FAQ & Clinical Guidance
1. Why is CHRNA4 gene testing recommended for nocturnal frontal lobe epilepsy?
This test directly detects the most common causative gene for autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE). Identifying a pathogenic CHRNA4 variant provides a definitive molecular diagnosis, enables accurate family risk stratification, and guides tailored treatment strategies.
2. What sample is required and how is home collection arranged?
A standard peripheral whole blood sample, extracted DNA, or a single drop on an FTA card is collected by a DHA-licensed phlebotomist at your residence. The specimen is transported via temperature-controlled cold-chain logistics to maintain integrity per ISO 9001:2015 standards. VIP Mobile Phlebotomy is available daily from 8 AM to 11 PM.
3. How long until I receive results and who interprets them?
Results are delivered within 3 to 4 weeks from sample receipt. A telephonic post-test guidance session with a Consultant Medical Geneticist is included to explain the clinical significance of findings and recommend appropriate next steps.
4. Does a positive result mean I will definitely develop epilepsy?
No. A pathogenic CHRNA4 variant indicates increased susceptibility but does not guarantee disease expression. Penetrance is incomplete and varies widely between families. Clinical correlation with seizure history, EEG, and family pedigree remains essential for accurate diagnosis and prognosis.
UAE Regulatory & Data Privacy Adherence
This service complies with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All genetic data is processed under strict confidentiality protocols with explicit patient consent. Clinical governance follows Federal Decree-Law No. 4 of 2016 on Medical Liability. Laboratory processing is performed at DNA Labs UAE, DHA Facility License No. 1143, ISO 9001:2015 certified (Cert: INT/EGQ/2509DA/3139).
Clinical & Logistical Metadata
| Test Name | CHRNA4 Gene Epilepsy, Nocturnal Frontal Lobe Type 1 Genetic Test |
| Price (AED) | 2,800 |
| Turnaround Time | 3โ4 Weeks |
| Sample Type / Matrix | Peripheral Whole Blood, Extracted DNA, or FTA Card โ VIP Mobile Phlebotomy and temperature-controlled cold-chain home collection available daily from 8 AM to 11 PM |
| Methodology Used | Next-Generation Sequencing (NGS) with Sanger Confirmation |
| ICD-10-CM Code | G40.0 |
| LOINC Code | 21636-6 |
| DHA Facility License & Laboratory Address | License No. 1143 โ Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE โ DNA Labs UAE |
ุฏุนู ุซูุงุฆู ุงููุบุฉ ู ุชุงุญ
ุงูุชุญูู ู ู ุงูุชุบุทูุฉ ุงูุชุฃู ูููุฉ
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
ุชููู ุนู ุงูุชุฎู ูู. ุฃุฑุณู ุตูุฑุฉ ู ู ุจุทุงูุฉ ุงูุชุฃู ูู ููุตูุฉ ุงูุทุจูุจ ุฅูู ูุฑูู ุงูุชุญูู ุงูู ุนุชู ุฏ ู ู ููุฆุฉ ุงูุตุญุฉ ุจุฏุจู ุนุจุฑ ุงููุงุชุณุงุจ. ุงุญุตู ุนูู ุชุญุฏูุซ ุงูุญุงูุฉ ูู ุฏูุงุฆู.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians